IDH1 and IDH2 are recurrently mutated in myeloid neoplasms, including myelodysplastic syndrome (5%‒10%), acute myeloid leukemia (10%‒20%), and MPN (1%‒5%), as well as in lymphoma and some solid cancers [14, 15, 16, 17, 18]. Here, IDH2 is linked to acute myeloid leukemia.